Newsletter September 2014

ICH M7 Step 4 implemented: ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK. What is up? Which products are affected? What is new? What is the timeline? Further reading? How can 2 Bridge help you?

Download Newsletter